File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Inhibition of histone deacetylases 1 and 3 protects injured retinal ganglion cells

TitleInhibition of histone deacetylases 1 and 3 protects injured retinal ganglion cells
Authors
Issue Date2013
Citation
Investigative Ophthalmology and Visual Science, 2013, v. 54, n. 1, p. 96-102 How to Cite?
AbstractPURPOSE. Thy-1 is a marker of retinal ganglion cell (RGC) differentiation. Optic nerve injury triggers reduction of Thy-1 promoter activation followed by retinal ganglion cell (RGC) death. This study determined whether MS-275, an inhibitor of the histone deacetylases 1 and 3, can inhibit these changes. METHODS. Mice expressing cyan fluorescent protein (CFP) under control of the Thy-1 promoter received MS-275 (subcutaneous) or vehicle three times per week starting 1 week before optic nerve crush and continuing for 6 weeks. The same retinal area was imaged using the blue-light confocal scanning laser ophthalmoscope before and after optic nerve crush every week, and fluorescent spots were counted manually. The eyes were then processed for histopathologic analysis. RESULTS. The mean proportions of fluorescent retinal neurons remaining in the vehicle group following optic nerve crush were 36 ± 8, 18 ± 6, 13 ± 10, 12 ± 4, 13 ± 5, and 13 ± 5% at weeks 1 through 6, respectively (n = 6). In contrast, the mean proportions of fluorescent retinal neurons remaining in the group treated with MS-275 were 59 ± 19, 39 ± 11, 34 ± 12, 33 ± 15, 32 ± 13, and 27 ± 15% at weeks 1 through 6, respectively (n = 7, P < 0.05 at weeks 1 through 5). Rate analysis showed that MS-275 slowed the rate of loss during the first 2 weeks by 23% (P < 0.05) and subsequently was similar. Histopathologic analysis revealed 27 ± 13% greater ganglion cell layer (GCL) neurons in the eyes from mice that received MS-275 treatment (P < 0.02). CONCLUSIONS. These results indicate that treatment with MS-275 protects against the loss of RGC differentiation and promotes RGC survival following optic nerve injury. © 2013 The Association for Research in Vision and Ophthalmology, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/298587
ISSN
2021 Impact Factor: 4.925
2020 SCImago Journal Rankings: 1.935
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChindasub, Panida-
dc.contributor.authorLindsey, James D.-
dc.contributor.authorDuong-Polk, Karen-
dc.contributor.authorLeung, Christopher K.-
dc.contributor.authorWeinreb, Robert N.-
dc.date.accessioned2021-04-08T03:08:49Z-
dc.date.available2021-04-08T03:08:49Z-
dc.date.issued2013-
dc.identifier.citationInvestigative Ophthalmology and Visual Science, 2013, v. 54, n. 1, p. 96-102-
dc.identifier.issn0146-0404-
dc.identifier.urihttp://hdl.handle.net/10722/298587-
dc.description.abstractPURPOSE. Thy-1 is a marker of retinal ganglion cell (RGC) differentiation. Optic nerve injury triggers reduction of Thy-1 promoter activation followed by retinal ganglion cell (RGC) death. This study determined whether MS-275, an inhibitor of the histone deacetylases 1 and 3, can inhibit these changes. METHODS. Mice expressing cyan fluorescent protein (CFP) under control of the Thy-1 promoter received MS-275 (subcutaneous) or vehicle three times per week starting 1 week before optic nerve crush and continuing for 6 weeks. The same retinal area was imaged using the blue-light confocal scanning laser ophthalmoscope before and after optic nerve crush every week, and fluorescent spots were counted manually. The eyes were then processed for histopathologic analysis. RESULTS. The mean proportions of fluorescent retinal neurons remaining in the vehicle group following optic nerve crush were 36 ± 8, 18 ± 6, 13 ± 10, 12 ± 4, 13 ± 5, and 13 ± 5% at weeks 1 through 6, respectively (n = 6). In contrast, the mean proportions of fluorescent retinal neurons remaining in the group treated with MS-275 were 59 ± 19, 39 ± 11, 34 ± 12, 33 ± 15, 32 ± 13, and 27 ± 15% at weeks 1 through 6, respectively (n = 7, P < 0.05 at weeks 1 through 5). Rate analysis showed that MS-275 slowed the rate of loss during the first 2 weeks by 23% (P < 0.05) and subsequently was similar. Histopathologic analysis revealed 27 ± 13% greater ganglion cell layer (GCL) neurons in the eyes from mice that received MS-275 treatment (P < 0.02). CONCLUSIONS. These results indicate that treatment with MS-275 protects against the loss of RGC differentiation and promotes RGC survival following optic nerve injury. © 2013 The Association for Research in Vision and Ophthalmology, Inc.-
dc.languageeng-
dc.relation.ispartofInvestigative Ophthalmology and Visual Science-
dc.titleInhibition of histone deacetylases 1 and 3 protects injured retinal ganglion cells-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1167/iovs.12-10850-
dc.identifier.pmid23197683-
dc.identifier.pmcidPMC3544425-
dc.identifier.scopuseid_2-s2.0-84874529569-
dc.identifier.volume54-
dc.identifier.issue1-
dc.identifier.spage96-
dc.identifier.epage102-
dc.identifier.eissn1552-5783-
dc.identifier.isiWOS:000314338400013-
dc.identifier.issnl0146-0404-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats